Committee Unblinds Phase III Zytiga Study
USPSTF and ACS Recommend Less Frequent Cervical Cancer Screenings and Pap Smears
Tobacco Control and Prevention Saved 795,000 Lives Between 1975-2000, Study Shows
Five-year Childhood ALL Survival Increased To 90.4 Percent by 2005
Study: CYP2D6 Genotypes Are Unreliable Predictors of Benefit
Study: Freezing Secondary Tumors Helpful in Metastatic Breast Cancer
Women Who Received CMF Chemotherapy Score Lower On Cognitive Skill Exams
Three Studies Demonstrate Oncotype DX Test Effectiveness
ACG Highlights Link Between Obesity and Colorectal Cancer
Olaparib Study Demonstrates No Changes In Overall Survival
Zelboraf Increased Overall Survival To 15.9 Months in Phase II Study
Trials Approved by NCI CTEP For the Month of March
Trending Stories
- Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad
- FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- U.S. News & World Report expands evaluation of outcomes in cancer subspecialties
- GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise - Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya - Vinay Prasad falls from grace at FDA upon flunking Trump political purity test
MAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies?
